Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Ex-LDP Health Panel Chief Calls for Changing Copay Rates for Different Drugs
February 13, 2017
- Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose Put Under Continued Discussion for Public Immunization Program
February 13, 2017
- PMDA Eyes 15-20% New Drug Review Fee Raise in April, Plan Now Up for Public Comments
February 13, 2017
- Japan’s First Guidance for Development of Cancer Immunotherapies Will Promote Development
February 13, 2017
- Drugs Subject to Optimal Use Guidelines Will Be a Rarity: Mori
February 13, 2017
- MHLW Weighs Use of Medical Bill Database for 4 Times Yearly Price Review: Nakayama
February 10, 2017
- MHLW Councilor Cites Cancer Meds for Conditional Early Approval Scheme
February 10, 2017
- MHLW Advisory Committee Backs Shionogi’s OIC Drug
February 10, 2017
- Post-Marketing Conditions Under “Conditional Early Approval System” Remain Unclear: MHLW Councilor Kazuhiko Mori
February 10, 2017
- 2nd Batch of Sakigake Designation Slated for Spring
February 9, 2017
- Chuikyo Panel to Draw Conclusion by Summer for FY2018 Rollout of Cost-Effective Assessment Scheme
February 9, 2017
- Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
- Chuikyo OKs Optimal Use Guidelines for Opdivo and Keytruda, Due Out Feb. 14
February 9, 2017
- PMDA to Delay Planned Staff Increase for Financial Reasons, Pace of Increase Has Slowed Down
February 9, 2017
- Keytruda Gets Same Daily Price as Opdivo; Chuikyo OKs Batch of Drugs for Feb. 15 Listing
February 8, 2017
- MHLW Notifies of Package Insert Changes for Iguratimod
February 8, 2017
- Sanofi’s VEGF Inhibitor Clears MHLW Advisory Panel for Colorectal Cancer
February 6, 2017
- MHLW Will Strictly Respond to Violations, Shiozaki Says on Fake Harvoni Issue
February 6, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW to Set Up Committee on Pharmaceutical and Medical Device Regulation at Health Sciences Council
February 2, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…